Prognostic significance of angiogenesis and blood vessel invasion in stage I non-small cell lung cancer after complete surgical resection

Chinese Journal of Lung Cancer

Volumn 10, Issue 1, 2007, Pages 29-33

  Zhou, Shijie ^a   Xu, Shaofa ^a   Zhang, Haiqing ^a   Liu, Zhidong ^a   Liang, Zikun ^a   Song, Xiaoyun ^a   Jiang, Ying ^a   Zhao, Dan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Blood vessel invasion (BVI); Lung neoplasms; Microvessel density (MVD); Vascular endothelial growth factor (VEGF)

Indexed keywords

CD34 ANTIGEN; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE;

EID: 33847391981     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Minna JD. Neoplasms of the lung. In: Fauci AS, Braunwald E, Isselbacher KJ, et al ed. Harrison's Principles of Internal Medicine. 14th ed. New York: McGraw-Hill, 1998. 552-562.
2. Ginsberg RJ, Vokes EE, Roben A, et al. Non-small cell lung cancer. In: Devita VT Jr, Hellman S, Rosenberg S, et al ed. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997. 858-911.
3. Strauss G. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage I non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol, 2004,23(Suppl) : 7019a.
4. Winton T. A prospective random trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage I non-small cell lung cancer (NSCLC) Intergroup (JBR). 10. Proc Am Soc Clin Oncol, 2004,23(Suppl) : 7018a.
5. Mineo TC, Ambrogi V, Baldi A, et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol, 2004,57(6) : 591-597.
6. Ohta Y, Nozawa H, Tanaka Y, et al. Increased vascular endothelial growth factor and vascular endothelial growth factor-c and decreased nm23 expression associated with microdissemination in the lymph nodes in stage 1 non-small cell lung cancer. J Thorac Cardiovasc Surg, 2000,119(4 Pt 1) : 804-813.
7. Yano T, Tanikawa S, Fujie T, et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer, 2000,36(5) : 601-609.
8. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med, 1991,324(1) : 1-8.
9. Saclarides TJ, Speziale NJ, Drab E, et al. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum, 1994,37(9) : 921-926.
10. Tomoda M, Maehara Y, Kakeji Y, et al. Intratumoral neovascularization and growth pattern in early gastric carcinoma. Cancer, 1999,85(11) : 2340-2346.
11. Toi M, Hoshina S, Takayanagi T, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res, 1994,85(10) : 1045-1049.
12. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol, 2001,8(1) : 72-79.
13. Ogawa J, Tsurumi T, Yamada S, et al. Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence. Cancer, 1994,73(4) : 1177-1183.
14. Shepherd FA, Sridhar SS. Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer, 2003,41(Suppl 1) : S63-S72.
15. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 2002,87(7) : 694-701.
16. D'Amico TA, Massey M, Herndon JE 2nd, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg, 1999,117(4) : 736-743.
17. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol, 1997,15(8) : 2858-2865.
18. Cox G, Jones JL, Walker RA, et al. Angiogenesis and non-small cell lung cancer. Lung Cancer, 2000,27(2) : 81-100.
19. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res, 2001,7(11) : 3410-3415.
20. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res, 1995,55(1) : 51-56.